LoPriore and affiliates disclose 21.46% Hepion (HEPA) ownership stake
Rhea-AI Filing Summary
Hepion Pharmaceuticals insider Vincent LoPriore and affiliated entities reported significant ownership of the company’s common stock. LoPriore beneficially owns 6,250,000 shares, equal to 21.46% of Hepion’s common stock, including 5,000,000 shares held through Gravitas Capital LP and 1,250,000 shares held by the Invictus Capital Advisors Pension Plan.
The filing states these shares were acquired for investment purposes for an aggregate purchase price of approximately $250,000. The reporting persons note they may acquire additional shares over time but currently have no other specific plans regarding corporate actions at Hepion.
Positive
- None.
Negative
- None.
Insights
LoPriore and affiliates disclose a 21.46% investment stake in Hepion.
Vincent LoPriore, Hepion’s Executive Chairman, reports beneficial ownership of 6,250,000 shares, or 21.46% of the company’s common stock. This includes 5,000,000 shares held via Gravitas Capital LP and 1,250,000 shares held by the Invictus Capital Advisors Pension Plan.
The filing describes the holdings as acquired for investment purposes, with the possibility of additional purchases. As a Schedule 13D, it highlights a sizable insider-aligned position, but does not itself announce operational changes, transactions, or strategic plans beyond potential future share acquisitions.